AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02289898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT03809117 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Biofire Film Array Gastrointestinal Panel
Description: The 22-target FilmArray® GI Panel allows a syndromic approach to the diagnosis of infectious diarrhea as it includes bacteria, viruses and parasites in one test. Results are typically available within two hours of collection.
Study NCT03809117 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Biofire Film Array Gastrointestinal Panel
Description: The 22-target FilmArray® GI Panel allows a syndromic approach to the diagnosis of infectious diarrhea as it includes bacteria, viruses and parasites in one test. Results are typically available within two hours of collection.
Study NCT04231864 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given intravenously (IV)
Study NCT04231864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Given orally (PO)
Study NCT01961609 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secukinumab (AIN457)
Description: Secukinumab was supplied in 150mg pre-filled syringes.
Study NCT00606333 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NEVO™ Sirolimus-eluting Coronary Stent System
Description: Intervention will consist of percutaneous coronary intervention for treatment of a single coronary lesion using standard coronary intervention techniques. Intervention in this arm will include treatment with the Conor Cobalt Chromium Sirolimus-eluting Coronary Stent System. Subjects assigned to the IVUS sub-study population will undergo intravascular ultrasound evaluation immediately post-stenting.
Study NCT00606333 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug-eluting stent (TAXUS Liberte Paclitaxel-eluting Coronary Stent System)
Description: Intervention will consist of percutaneous coronary intervention for treatment of a single coronary lesion using standard coronary intervention techniques. Intervention in this arm will include treatment with the TAXUS Liberte Paclitaxel-eluting Coronary Stent System. Subjects assigned to the IVUS sub-study population will undergo intravascular ultrasound evaluation immediately post-stenting.
Study NCT03764020 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule/placebo comparator
Description: 3 mg placebo capsule one hour before bedtime for three weeks along with life style modification according to ACC/AHA 2013 guideline
Study NCT03764020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin/experimental
Description: Melatonin ,capsule, 3 mg, one dose one hour before bedtime, for three weeks along with life style modification according to ACC/AHA 2013 guideline.
Study NCT03132688 — intervention group
Intervention type: DRUG
Intervention: Propofol
Description: Intravenous administration with dose of 100-200mcg/kg/min
Study NCT04305197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICP-022
Description: Tablet, 50mg, once a day, oral, will be administered for 12 weeks in double-blind treatment period
Study NCT04305197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICP-022
Description: Tablet, 80mg, once a day, oral, will be administered for 12 weeks in double-blind treatment period
Study NCT04305197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICP-022
Description: Tablet, 100mg, once a day, oral, will be administered for 12 weeks in double-blind treatment period
Study NCT04305197 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Tablet, matched to ICP-022, once a day, oral, will be administered for 12 weeks in double-blind treatment period
Study NCT03627637 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy nuts
Description: Study volunteers will receive daily 70 g of soy nuts (roasted soybeans containing approximately 100 mg isoflavones). The amount of soy protein provided by the nuts equals the FDA recommended daily intake of 25-30 g.
Study NCT04624139 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy + physiotherapy
Description: Combined intervention of stress reducing I-CBT and physiotherapy. The intervention consists of two components; I-CBT and physiotherapy aiming to reduce symptoms of stress.~I-CBT: Designed to reduce stress, during 8 weeks. Physiotherapy: A total of three visits with a physiotherapist (at start, after 4 weeks and after 12 weeks). Visit 1 (at start): The participant and the physiotherapist design together an individual plan of physical activity, based on the recommendations for stress as suggested in the Physical Activity in the Prevention and Treatment of Disease (FYSS in Swedish): Physical activity on moderate intensity 150 min/week and a strengthening exercise program performed at twice a week.~The physical activity is performed outside health care - in the participant´s home or in other exercise premises outside health care Visit 2 and 3 (after 4 and 12 weeks): Follow up and revision of the Physical activity plan.
Study NCT04624139 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy only
Description: A total of three visits with a physiotherapist (at start, after 4 weeks and after 12 weeks). Visit 1 (at start): The participant and the physiotherapist design together an individual plan of physical activity, based on the recommendations for stress as suggested in the Physical Activity in the Prevention and Treatment of Disease (FYSS in Swedish): Physical activity on moderate intensity 150 min/week and a strengthening exercise program performed at twice a week.~The physical activity is performed outside health care - in the participant´s home or in other exercise premises outside health care Visit 2 and 3 (after 4 and 12 weeks): Follow up and revision of the Physical activity plan.
Study NCT03489369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym022
Description: Sym022 is a recombinant, fully human antibody that binds LAG-3 and blocks the LAG-3/major histocompatibility complex class II (MHC-II) interaction, thus allowing for increased T-cell proliferation and cytokine production.
Study NCT03113409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: Buprenorphine will be administered daily
Study NCT03113409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: On study day 2, participants will receive increasing doses of oral naltrexone prior to administration of XR-NTX
Study NCT03113409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vivitrol
Description: Participants will receive one 380 i.m. injection on Study day 5 or 10, and another injection 4 weeks later.
Study NCT03651921 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CTS-BC-CH
Description: CTS-BC-CH is a standardized program with 7 weekly group sessions (2.5. to 3 hours). The CTS-BC-CH focuses on building skills, sharing experiences, and support among the participants.~Program elements are: Brainstorming, action plan formulation, action plan feedback, problem solving, and decision making.
Study NCT04517474 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CANreduce
Description: CANreduce is an automated web-based self-help tool based on classical Cognitive Behavioral Treatment (CBT) approaches for treating cannabis dependence. It will consist of a consumption diary, eight modules designed to reduce cannabis use based on the principles of motivational interviewing, self-control practices, and methods of cognitive behavioral therapy ( strategies for goal achievement, Identifying risk situations, Dealing with cannabis craving, Dealing with relapses, Working on needs, Saying no to foster refusal skills, Dealing with burdens, Preserving achievements). Participants can study all modules at their own pace and order, though a specific order will be advised.
Study NCT04517474 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychological support
Description: psychological support
Study NCT04435860 — intervention group
Intervention type: OTHER
Intervention: Truncal flexion-extension muscle power
Description: Patient performs a maximum truncal flexion laying supine on the bed with cap of muscle tester placed on sternum,
Study NCT01612286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: endostatin
Description: Gemcitabine 1.0g/m2 d1,8 cisplatin 80mg/m2 endostatin 15mg/d 14days/cycle \*4cycles
Study NCT04417218 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lysine
Description: Lysine is an essential amino acid which is acquired from dietary sources.
Study NCT04435860 — intervention group
Intervention type: OTHER
Intervention: Truncal extension muscle power
Description: Patient performs a maximum truncal extension laying prone on the bed while the cap of manual muscle tester placed on vertebrae at the level of midline between superior angles of scapulae.
Study NCT04417218 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Controlled Diet
Description: Individuals will be instructed to consume specific foods, to adhere to a controlled lysine diet.
Study NCT04435860 — intervention group
Intervention type: OTHER
Intervention: Cervical flexion muscle power
Description: Patient performs a maximum cervical flexion sitting while the cap of manual muscle tester placed on the middle of the forehead.
Study NCT04435860 — intervention group
Intervention type: OTHER
Intervention: Cervical extension muscle power
Description: Patient performs a maximum cervical extension sitting while the cap of manual muscle tester placed on protuberantia occipitalis.
Study NCT04435860 — intervention group
Intervention type: OTHER
Intervention: Cervical lateral flexion muscle powers
Description: Patient performs a maximum cervical lateral flexions on right and left sitting while the cap of manual muscle tester placed on relevant pterion.
Study NCT04435860 — intervention group
Intervention type: OTHER
Intervention: Shoulder flexion muscle power
Description: Patient performs a maximum shoulder flexion of the dominant side on upright while the cap of manual muscle tester placed on midpoint of the line between anterior aspect of acromion and anterior elbow.
Study NCT04435860 — intervention group
Intervention type: OTHER
Intervention: Shoulder extension muscle power
Description: Patient performs a maximum shoulder flexion of the dominant side on upright while the cap of manual muscle tester placed on midpoint of the line between posterior aspect of acromion and posterior elbow.
Study NCT04435860 — intervention group
Intervention type: OTHER
Intervention: Shoulder internal rotation muscle power
Description: Patient performs a maximum shoulder internal rotation of the dominant side on upright while the cap of manual muscle tester placed on midpoint of the line between anterior elbow and wrist.
Study NCT02925078 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Biohorizons Tapered Internal Implant, Laser-Lok, Resorbable Blast Textured (RBT)
Description: Placement of implant in a subject with \<2 mm mucosa thickness or a subject with ≥2 mm mucosa thickness.
Study NCT04435860 — intervention group
Intervention type: OTHER
Intervention: Shoulder external rotation muscle power
Description: Patient performs a maximum shoulder external rotation of the dominant side on upright while the cap of manual muscle tester placed on midpoint of the line between posterior elbow and wrist.
Study NCT04435860 — intervention group
Intervention type: OTHER
Intervention: Shoulder abduction muscle power
Description: Patient performs a maximum shoulder abduction of the dominant side on upright while the cap of manual muscle tester placed on midpoint of the line lateral aspect of acromion and lateral epicondyle.
Study NCT04435860 — intervention group
Intervention type: OTHER
Intervention: Hip flexion muscle power
Description: Patient performs a maximum hip flexion laying supine on the bed while the cap of manual muscle tester placed on middle of the anterior thigh.
Study NCT04435860 — intervention group
Intervention type: OTHER
Intervention: Hip extension muscle power
Description: Patient performs a maximum hip extension laying prone on the bed while the cap of manual muscle tester placed on middle of the posterior thigh.
Study NCT02555306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5 mg of DE-122
Description: DE-122 Injectable Solution
Study NCT04435860 — intervention group
Intervention type: OTHER
Intervention: Hip abduction muscle power
Description: Patient performs a maximum hip abduction laying supine on the bed while the cap of manual muscle tester placed on middle of the lateral thigh.
Study NCT04435860 — intervention group
Intervention type: OTHER
Intervention: Hip internal rotation muscle power
Description: Patient performs a maximum hip internal rotation laying supine on the bed while the cap of manual muscle tester placed on the midline between lateral condyle of femur and lateral malleolus.
Study NCT04435860 — intervention group
Intervention type: OTHER
Intervention: Hip external rotation muscle power
Description: Patient performs a maximum hip external rotation laying supine on the bed while the cap of manual muscle tester placed on the midline between medial condyle of femur and medial malleolus.
Study NCT04435860 — intervention group
Intervention type: OTHER
Intervention: Bath Ankylosing Spondylitis Functional Index (BASFI)
Description: This questionnaire evaluates the functionality in patients with AS. The ten questions that comprise the BASFI were chosen with input from patients with AS. The first 8 questions evaluate activities related to functional anatomical limitations due to the course of this inflammatory disease. The final 2 questions evaluate the patients' ability to cope with everyday life. A visual analogue scale (with 0 being easy and 10 impossible) is used to answer the questions on the test. The final score varies between 0 and 10.
Study NCT04435860 — intervention group
Intervention type: OTHER
Intervention: Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)
Description: This questionnaire evaluates the disease activity level in patients with AS. The BASDAI consists of a 0 - 10 scale measuring discomfort, pain, and fatigue (0 being no problem and 10 being the worst problem) in response to six questions asked of the patient pertaining to the five major symptoms of AS. The final score varies between 0 and 10.
Study NCT02555306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.0 mg of DE-122
Description: DE-122 Injectable Solution
Study NCT02555306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.0 mg of DE-122
Description: DE-122 Injectable Solution
Study NCT04435860 — intervention group
Intervention type: OTHER
Intervention: The Health assessment questionnaire (HAQ)
Description: The Health assessment questionnaire (HAQ) is a questionnaire for the assessment of disability in an individual. The patients report the amount of difficulty they have in performing eight daily living activities. Each question asks on a scale ranging from 0 to 3 if the categories can be performed without any difficulty (scale 0) up to cannot be done at all (scale 3). The final score varies between 0 and 3.
Study NCT04435860 — intervention group
Intervention type: OTHER
Intervention: Bath Ankylosing Spondylitis Metrology Index (BASMI)
Description: Bath Ankylosing Spondylitis Metrology Index, a combined index to assess the spinal mobility. It evaluates the patients regarding cervical rotation, tragus-to-wall distance, lumbar flexion, lumbar lateral flexion and intermalleolar distance. The total score varies between 5 to 15 in patients with ankylosing spondylitis
Study NCT02891083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (Paclitaxel and Cisplatin)
Description: Adjuvant chemotherapy group: three cycles: (Paclitaxel: 175mg/m2 ivgtt, 3h, d1 4week × 3 and cisplatin: 75mg/m2 ivgtt, d1 4 week × 3)
Study NCT01057576 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: An alcoholic extract of Artemisia dracunculus L.
Description: capsule, daily dosing
Study NCT01057576 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsule, daily dosage
Study NCT03582865 — intervention group
Intervention type: DRUG
Intervention: Tamoxifen 20 mg
Description: Tamoxifen 20 mg is a selective estrogen receptor modulator
Study NCT04506216 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cohort
Description: During a regular follow-up visit, the following data will be collected:~* questionnaires on lifestyle, eating custom (SCOFF-F, 5th question of the m-SCOFF) and physical activity (IPAQ)~* bio-electric impedance analysis~* insulin pump and sensor data collection
Study NCT04793451 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Endurance training
Description: The women in group A underwent endurance exercise on cycle ergometers (Schwinn Evolution, Schwinn Bicycle Company, Boulder, Colorado, USA). Exercise sessions consisted of a five-minute warm-up (stretching exercise) at low intensity (50%-60% of maximum heart rate), a 45-minute exercise (at 50%-80% of maximum heart rate), five minutes of cycling without a load, and five minutes of closing stretching and breathing exercise of low intensity.
Study NCT04793451 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Endurance-strength training
Description: Group B performed endurance-strength exercise consisting of a five-minute warm-up (stretching exercises) of low intensity (50%-60% of maximum heart rate), a strength component, an endurance component, 5 minutes cycling without a load, and a 5 minutes closing stretching and breathing exercise of low intensity. The 20-minute-long strength component was performed using a neck barbell and a gymnastic ball. Directly after the strength exercise, the women took part in a 25-minute endurance exercise on cycle ergometers (Schwinn Evolution, Schwinn Bicycle Company, Boulder, Colorado, USA) at 50%-80% of maximum heart rate.
Study NCT02652208 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online decision aid
Description: The Healthwise online shared decision point for Stable Chest Discomfort
Study NCT02652208 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video decision aid
Description: The Health Dialog DVD and booklet decision aid for Stable Chest Discomfort
Study NCT02891083 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy
Description: Target: the upper mediastinum and bilateral supraclavicular region (Upper bound: thyrocricoid, lower bound: carina of 3cm)~Dose: 50Gy~Technology: strong tone~Segmentation: conventional segmentation 2Gy/d
Study NCT02891083 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control group (Surgery alone)
Study NCT03123653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg IFN 2b
Description: Peg IFN 2b 1.5mcg/kg once every week for 48 weeks
Study NCT01602146 — intervention group
Intervention type: OTHER
Intervention: ultramarathon running
Description: * blood samples before and after ultramarathon~* urinary samples before and after ultramarathon~* voluntary ant electrically muscular forces measuring before and after ultramarathon~* Broadband ultrasound Attenuation before and after ultramarathon
Study NCT00545168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spinosad
Description: 10 minute topical application of product, followed by a complete rinse off.
Study NCT00545168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spinosad
Description: 10 minute topical application followed by a complete rinse off, followed by a nit combing regimen.
Study NCT00545168 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Permethrin 1%
Description: Topical application for 10 minutes, followed by a complete rinse off, followed by a nit combing regimen
Study NCT00347438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine twice daily for 14 days followed by 7 days without taking drug (1 cycle). This schedule is followed for 8 cycles (about 24 weeks).
Study NCT01973387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Up to 6 cycles (total of 8 doses administered by intravenous infusion): 375 mg/m2 on Day 1 of Cycle 1, 500 mg/m2 on Day 15 of Cycle 1 (Weeks 1-4); 500 mg/m2 on Day 1 and Day 15 of Cycle 2 (Weeks 5-8); and 500 mg/m2 on Day 1 of Cycles 3-6 (Weeks 9-24).
Study NCT01973387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: 420 mg capsules administered by mouth daily until disease progression or unacceptable toxicity, whichever occurs first.
Study NCT01581489 — intervention group
Intervention type: PROCEDURE
Intervention: Time to clamping of the umbilical cord after delivery
Description: The time after delivery of the newborn until the midwife stops the circulation in the umbilical cord with a clamp.
Study NCT02545517 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rabipur
Description: Participants in all the groups received Rabipur vaccine booster dose, administered intramuscularly in the deltoid region of the non-dominant arm.
Study NCT01352416 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranolazine
Description: Ranolazine 1000mg (2-500mg tablets) twice daily. Starting 2 days prior to surgery, morning of surgery and up to 14 days post operative depending when the breathing tube is removed from the patient post operative. If intolerant to the study drug due to adverse effects or the patient is started on diltiazem or verapamil post operative then the dose will be reduced to 500mg (1-500mg tablet) twice daily
Study NCT01352416 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1000mg (2-500mg tablets) twice daily. Starting 2 days prior to surgery, morning of surgery and up to 14 days post operative depending when the breathing tube is removed from the patient post operative. If intolerant to the study drug due to adverse effects or the patient is started on diltiazem or verapamil post operative then the dose will be reduced to 500mg (1-500mg tablet) twice daily
Study NCT03095638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional dolutegravir 10 mg tablet
Description: Single dose of five 10 mg DTG tablets will be administered directly to mouth with 240 mL of water in the morning to randomized subjects in fasting state present in Part 1. DTG will be a white, round shaped, biconvex tablet.